Logo
Registracija
Postani član

Publikacije (219)

Nazad
Filters

Filteri

Datum objave

Uključeni istraživači

Dodatni filteri

FIRST RESULTS OF A‐PREDICT: A PHASE II STUDY OF AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CANCER (RCC) UNSUITABLE FOR NEPHRECTOMY: PNFLBA‐16
1. 4. 2017.
0
G. Stewart, J. Morden, E. Boleti, N. Vasudev, F. Thistlethwaite, A. Michael, L. Kilburn, Rebecca Lewis et al.

Preuzmi PDF
Vidi više
Current management of renal cell cancer
1. 3. 2017.
2
L. Spain, S. Turajlic

Preuzmi PDF
Vidi više
Immunity Report Fc-Optimized Anti-CD 25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
2017.
8
F. Vargas, A. Furness, I. Solomon, K. Joshi, L. Mekkaoui, Marta H. Lesko, E. Rota, R. Dahan et al.

Preuzmi PDF
Vidi više
Tracking the Evolution of Non-Small-Cell Lung Cancer
2017.
16
G. A. Wilson, N. Mcgranahan, N. Birkbak, T. Watkins, S. Veeriah, S. Shafi, D. Johnson, R. Mitter et al.

Preuzmi PDF
Vidi više
University of Birmingham Tracking the Evolution of Non-Small-Cell Lung Cancer
2017.
0
G. A. Wilson, N. Mcgranahan, N. Birkbak, T. Watkins, S. Veeriah, S. Shafi, D. Johnson, R. Mitter et al.

Preuzmi PDF
Vidi više
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.
2017.
95
L. Spain, G. Walls, M. Julve, K. O’Meara, T. Schmid, E. Kalaitzaki, S. Turajlic, M. Gore et al.
Annals of Oncology

Preuzmi PDF
Vidi više
Systemic treatment of advanced papillary renal cell carcinoma: Where next?
1. 12. 2016.
2
S. Turajlic, J. Larkin
European Journal of Cancer

Preuzmi PDF
Vidi više
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
25. 10. 2016.
134
L. Spain, Gerard Walls, Maximilian Julve, K. O’Meara, Thomas A. Schmid, E. Kalaitzaki, S. Turajlic, M. Gore et al.
Annals of Oncology

Preuzmi PDF
Vidi više
Patterns of steroid use in diarrhoea and/or colitis (D/C) from immune checkpoint inhibitors (ICPI)
1. 10. 2016.
5
L. Spain, S. Diem, K. Khabra, S. Turajlic, M. Gore, N. Yousaf, J. Larkin

Preuzmi PDF
Vidi više
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.
1. 6. 2016.
137
L. Spain, Robert Higgins, K. Gopalakrishnan, S. Turajlic, M. Gore, J. Larkin
Annals of Oncology

Preuzmi PDF
Vidi više
ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma.
20. 5. 2016.
6
Mark Stares, S. Turajlic, A. Furness, K. Joshi, D. Nicol, M. Gore, L. Pickering, N. Fotiadis et al.

Preuzmi PDF
Vidi više
Defining the mechanisms of response and resistance to anti-PD-1 therapy: An exploratory phase II study of pembrolizumab in advanced melanoma (ADAPTeM).
20. 5. 2016.
0
K. Joshi, A. Furness, T. Oakes, J. Heather, L. Spain, Y. Wong, A. B. Aissa, Mark Stares et al.

Preuzmi PDF
Vidi više
Metastasis as an evolutionary process
8. 4. 2016.
549
S. Turajlic, C. Swanton
Science

Preuzmi PDF
Vidi više
217 Identifying the metastatic subclone by exhaustive sampling of primary and metastasis in clear cell renal cell carcinoma (ccRCC) pair
1. 3. 2016.
2
A. Soultati, T. O'brien, B. Challacombe, D. Nicol, S. Horswell, Hang Xu, A. Rowan, J. López et al.

Preuzmi PDF
Vidi više
114 Clonal mTOR pathway activation as a predictive biomarker for mTOR inhibitor therapy in clear cell renal cell carcinoma
1. 3. 2016.
0
Mark Stares, D. Nicol, T. O'brien, B. Challacombe, A. Rowan, S. Horswell, M. Salm, A. Soultati et al.

Preuzmi PDF
Vidi više

Nema pronađenih rezultata, molimo da izmjenite uslove pretrage i pokušate ponovo!

Pretplatite se na novosti o BH Akademskom Imeniku

Početna
Pretraga
Prijavi se

Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo

Saznaj više